Prelude Therapeutics (PRLD) Stock Chart & Stock Price History $1.04 -0.06 (-5.45%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Prelude Therapeutics Stock Price Performance The Prelude Therapeutics (PRLD) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 73.33%, with a year-to-date return of -18.43%. In the past month, the stock has increased 4.00%, reflecting recent market activity. As of the latest close, Prelude Therapeutics traded at $1.04 with a market cap of $58.72 million and volume of 87,405 shares. Receive PRLD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+0.97%1 Month Performance+4.00%3 Month Performance+47.12%Year-To-Date Performance-18.43%1 Year Performance-73.33% PRLD Stock Chart for Friday, June, 13, 2025 PRLD Chart by TradingView Prelude Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/12/2025$1.10$1.04-5.02%$1.09$1.0087,405 shs$58.72 million06/11/2025$1.08$1.10+1.39%$1.16$1.06224,033 shs$61.82 million06/10/2025$1.18$1.08-8.47%$1.25$1.03381,120 shs$60.98 million06/09/2025$1.03$1.18+14.56%$1.20$1.04365,898 shs$66.62 million06/06/2025$0.98$1.03+5.30%$1.04$0.94122,504 shs$58.15 million06/05/2025$1.00$0.98-2.17%$1.03$0.9382,412 shs$55.23 million06/04/2025$0.94$1.00+6.91%$1.01$0.94151,788 shs$56.45 million06/03/2025$0.91$0.94+3.11%$0.98$0.91203,597 shs$52.81 million06/02/2025$0.90$0.91+0.84%$0.92$0.8597,853 shs$51.22 million05/30/2025$0.90$0.90-0.27%$0.91$0.8769,734 shs$50.79 million Get the Latest News and Ratings for PRLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/29/2025$0.87$0.90+3.67%$0.91$0.8341,516 shs$50.92 million05/28/2025$0.80$0.87+8.80%$0.92$0.77382,509 shs$49.12 million05/27/2025$0.89$0.80-9.77%$0.92$0.78590,004 shs$45.15 million05/26/2025$0.89$0.89$0.89$0.8374,248 shs$50.04 million05/23/2025$0.90$0.89-1.54%$0.89$0.8374,248 shs$50.04 million05/22/2025$0.91$0.90-1.53%$0.94$0.9010,143 shs$50.82 million05/21/2025$0.98$0.91-6.91%$0.99$0.8567,429 shs$51.61 million05/20/2025$0.92$0.98+6.31%$1.00$0.8993,683 shs$55.44 million05/19/2025$0.88$0.92+4.59%$0.93$0.84137,153 shs$52.15 million05/16/2025$0.94$0.88-5.74%$0.93$0.86139,927 shs$38.52 million05/15/2025$0.90$0.94+3.78%$1.05$0.89122,592 shs$40.86 million05/14/2025$1.00$0.90-9.71%$1.03$0.90152,443 shs$39.38 million05/13/2025$0.88$1.00+13.29%$1.08$0.88367,874 shs$43.61 million05/12/2025$0.78$0.88+13.02%$0.90$0.8258,847 shs$38.50 million Related Companies enGene Stock Price Chart scPharmaceuticals Stock Price Chart CytomX Therapeutics Stock Price Chart Bright Minds Biosciences Stock Price Chart CARGO Therapeutics Stock Price Chart Innate Pharma Stock Price Chart Nanobiotix Stock Price Chart Instil Bio Stock Price Chart SOPHiA GENETICS Stock Price Chart biote Stock Price Chart Receive PRLD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PRLD) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
